Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

References

• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. World Drug Report 2015. [cited 2015 Oct 20]. Available from: http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
   Google Scholar
• Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–2296.
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444–459.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15-4927, NSDUH Series H-50. 2015 [cited 2015 Oct 20]. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2014. Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-71, HHS Publication No. (SMA) 14-4850. Rockville (MD): Substance Abuse and Mental Health Services Administration. [cited 2015 Oct 20]. Available from: http://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf
   Google Scholar
• Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297:249–251.
   PubMed Web of Science ®Google Scholar
• Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18:228–245.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(Suppl.):ES9–E38.
   PubMed Web of Science ®Google Scholar
• Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;78:1159–1166.
   PubMed Web of Science ®Google Scholar
• McCabe SE, Cranford JA, Boyd CJ, et al. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32:562–575.
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Edlund MJ, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006;166:2087–2093.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–667.
   PubMed Web of Science ®Google Scholar
• Meyer R, Patel AM, Rattana SK, et al. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014;17:372–387.
   PubMed Web of Science ®Google Scholar
• Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–217.
   PubMed Web of Science ®Google Scholar
• Kirsh K, Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. J Pain Palliat Care Pharmacother. 2012;26:348–361.
   PubMedGoogle Scholar
• Farré M, Camí J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86:1601–1606.
   PubMedGoogle Scholar
• Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8–18.
   PubMed Web of Science ®Google Scholar
• Gudin JA, Mogali S, Jones JD, et al. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125:115–130.
   PubMed Web of Science ®Google Scholar
• Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83(Suppl. 1):S31–S39.
   PubMed Web of Science ®Google Scholar
• Schifano F, Deluca P, Baldacchino A, et al. Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:640–646.
   PubMed Web of Science ®Google Scholar
• Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23:1–9.
   PubMed Web of Science ®Google Scholar
• Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20:5–13.
   PubMedGoogle Scholar
• Carise D, Dugosh KL, McLellan AT, et al. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750–1756.
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–1154.
   PubMed Web of Science ®Google Scholar
• Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92:267–276.
   PubMed Web of Science ®Google Scholar
• Katz N, Fernandez K, Chang A, et al. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008;24:528–535.
   PubMed Web of Science ®Google Scholar
• Butler SF, Black RA, Serrano JM, et al. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J Opioid Manag. 2010;6:239–252.
   PubMedGoogle Scholar
• Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29.
   PubMed Web of Science ®Google Scholar
• Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30:334–341.
   PubMed Web of Science ®Google Scholar
• Vietri J, Joshi AV, Barsdorf AI, et al. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med. 2014;15:2064–2074.
   PubMed Web of Science ®Google Scholar
• Krüger R, Meißner W, Zimmer A. [Misuse of opioid analgesics. An Internet analysis]. Schmerz. 2014;28:473–482. German.
   PubMed Web of Science ®Google Scholar
• Farhat S, Hussain SS, Rather YH, et al. Sociodemographic profile and pattern of opioid abuse among patients presenting to a de-addiction centre in tertiary care Hospital of Kashmir. J Basic Clin Pharm. 2015;6:94–97.
   PubMedGoogle Scholar
• Peacock A, Bruno R, Cama E, et al. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug Alcohol Rev. 2015;34:611–622.
   Web of Science ®Google Scholar
• Butler SF, Fernandez KC, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010;11:67–80.
   PubMed Web of Science ®Google Scholar
• Villapiano A, Butler SF, Budman SH, et al. Demonstration of the feasibility of real-time, product-specific, prescription opioid abuse surveillance: the NAVIPPRO system. Poster presented at: Annual Meeting of the College on Problems of Drug Dependence; 2006 Jun 20; Scottsdale, AZ. Poster 173.
   Google Scholar
• Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90:64–71.
   PubMed Web of Science ®Google Scholar
• Arvanitis ML, Satonik RC. Transdermal fentanyl abuse and misuse. Am J Emerg Med. 2002;20:58–59.
   PubMed Web of Science ®Google Scholar
• Liappas IA, Dimopoulos NP, Mellos E, et al. Oral transmucosal abuse of transdermal fentanyl. J Psychopharmacol. 2004;18:277–280.
   PubMed Web of Science ®Google Scholar
• Woodall KL, Martin TL, McLellan BA. Oral abuse of fentanyl patches (Duragesic®): seven case reports. J Forensic Sci. 2008;53:222–225.
   PubMed Web of Science ®Google Scholar
• Bektas F, Eken C, Sayrac V. Opioid toxicity as a result of oral/transmucosal administration of transdermal fentanyl patch. Eur J Emerg Med. 2009;16:344–345.
   PubMed Web of Science ®Google Scholar
• Van Rijswijk R, Van Guldener C. A delirious patient with opioid intoxication after chewing a fentanyl patch. J Am Geriatr Soc. 2006;54:1298–1299.
   PubMed Web of Science ®Google Scholar
• Carson HJ, Knight LD, Dudley MH, et al. A fatality involving an unusual route of fentanyl delivery: chewing and aspirating the transdermal patch. Leg Med (Tokyo). 2010;12:157–159.
   PubMed Web of Science ®Google Scholar
• Faust AC, Terpolilli R, Hughes DW. Management of an oral ingestion of transdermal fentanyl patches: a case report and literature review. Case Rep Med. 2011;2011:495938.
   PubMedGoogle Scholar
• Thomas S, Winecker R, Pestaner JP. Unusual fentanyl patch administration. Am J Forensic Med Pathol. 2008;29:162–163.
   PubMed Web of Science ®Google Scholar
• Mrvos R, Feuchter AC, Katz KD, et al. Whole fentanyl patch ingestion: a multi-center case series. J Emerg Med. 2012;42:549–552.
   PubMed Web of Science ®Google Scholar
• Reeves MD, Ginifer CJ. Fatal intravenous misuse of transdermal fentanyl. Med J Aust. 2002;177:552–553.
   PubMed Web of Science ®Google Scholar
• Lilleng PK, Mehlum LI, Bachs L, et al. Deaths after intravenous misuse of transdermal fentanyl. J Forensic Sci. 2004;49:1364–1366.
   PubMed Web of Science ®Google Scholar
• Tharp AM, Winecker RE, Winston DC. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol. 2004;25:178–181.
   PubMed Web of Science ®Google Scholar
• Marquardt KA, Tharratt RS. Inhalation abuse of fentanyl patch. Clin Toxicol. 1994;32:75–78.
   Web of Science ®Google Scholar
• Chapman E, Leipsic J, Satkunam N, et al. Pulmonary alveolar proteinosis as a reaction to fentanyl patch smoke. Chest. 2012;141:1321–1323.
   PubMed Web of Science ®Google Scholar
• Coon TP, Miller M, Kaylor D, et al. Rectal insertion of fentanyl patches: a new route of toxicity. Ann Emerg Med. 2005;46:473.
   PubMed Web of Science ®Google Scholar
• Barrueto F Jr, Howland MA, Hoffman RS, et al. The fentanyl tea bag. Vet Hum Toxicol. 2004;46:30–31.
   PubMedGoogle Scholar
• Darling SS, Mærkedahl R. [Fentanyl tea]. Ugeskr Laeger. 2014;17:176(8A). Danish.
   Google Scholar
• Schauer CK, Shand JA, Reynolds TM. The fentanyl patch boil-up – a novel method of opioid abuse. Basic Clin Pharmacol Toxicol. 2015;117:358–359.
   PubMed Web of Science ®Google Scholar
• Vidal-Trecan G, Varescon I, Nabet N, et al. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003;69:175–181.
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Fatséas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13(Suppl. 1):S17–S28.
   PubMed Web of Science ®Google Scholar
• Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75–78.
   PubMed Web of Science ®Google Scholar
• Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia: an update. Drug Alcohol Rev. 2008;27:197–199.
   PubMed Web of Science ®Google Scholar
• Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28–41.
   PubMedGoogle Scholar
• Häkkinen M, Heikman P, Ojanperä I. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning. Forensic Sci Int. 2013;232:11–15.
   PubMed Web of Science ®Google Scholar
• Strang J. Abuse of buprenorphine (Temgesic) by snorting. BMJ. 1991;302:969.
   PubMed Web of Science ®Google Scholar
• Roux P, Villes V, Bry D, et al. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict Behav. 2008;33:1625–1629.
   PubMed Web of Science ®Google Scholar
• Horyniak D, Dietze P, Larance B, et al. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. Int J Drug Policy. 2011;22:167–171.
   PubMed Web of Science ®Google Scholar
• Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21–27.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat. 2014;47:27–34.
   PubMed Web of Science ®Google Scholar
• Back SE, Payne RA, Waldrop AE, et al. Prescription opioid aberrant behaviors: a pilot study of sex differences. Clin J Pain. 2009;25:477–484.
   PubMed Web of Science ®Google Scholar
• Back SE, Payne RL, Simpson AN, et al. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav. 2010;35:100–107.
   Web of Science ®Google Scholar
• Kerridge BT, Saha TD, Chou SP, et al. Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions – III. Drug Alcohol Depend. 2015;156:47–56.
   PubMed Web of Science ®Google Scholar
• Back SE, Payne RL, Wahlquist AH, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011;37:313–323.
   PubMed Web of Science ®Google Scholar
• Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J. 2010;7:24.
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11:469–479.
   PubMedGoogle Scholar
• Havens JR, Oser CB, Leukefeld CG. Injection risk behaviors among rural drug users: implications for HIV prevention. AIDS Care. 2011;23:638–645.
   PubMed Web of Science ®Google Scholar
• Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107:1318–1327.
   PubMed Web of Science ®Google Scholar
• Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health. 2014;104:816–821.
   PubMed Web of Science ®Google Scholar
• Zibbell JE, Hart-Malloy R, Barry J, et al. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104:2226–2232.
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and hepatitis C virus among young injection drug users. Drugs (Abingdon Engl). 2015;22:35–42.
   PubMedGoogle Scholar
• Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone–Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:443–444.
   PubMed Web of Science ®Google Scholar
• Bouquié R, Wainstein L, Pilet P, et al. Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. PLoS One. 2014;9:e113991.
   PubMed Web of Science ®Google Scholar
• Wainstein L, Bernier C, Gérardin M, et al. Livedo-like dermatitis and necrotic lesions after high-dose buprenorphine injections: a national French survey. Br J Dermatol. 2015;172:1412–1414.
   PubMed Web of Science ®Google Scholar
• Marchiori E, Lourenço S, Gasparetto TD, et al. Pulmonary talcosis: imaging findings. Lung. 2010;188:165–171.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Chan ES, Chou SH, et al. Pulmonary effects of i.v. injection of crushed oral tablets: “excipient lung disease”. AJR Am J Roentgenol. 2014;203:W506–W515.
   PubMed Web of Science ®Google Scholar
• Chong E, Poh KK, Shen L, et al. Infective endocarditis secondary to intravenous Subutex abuse. Singapore Med J. 2009;50:34–42.
   PubMed Web of Science ®Google Scholar
• Ho RC, Ho EC, Tan CH, et al. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009;35:199–202.
   PubMed Web of Science ®Google Scholar
• Tookes H, Diaz C, Li H, et al. A cost analysis of hospitalizations for infections related to injection drug use at a county safety-net hospital in Miami, Florida. PLoS One. 2015;10:e0129360.
   PubMed Web of Science ®Google Scholar
• Alexander D, Alexander K, Valentino J. Intranasal hydrocodone-acetaminophen abuse induced necrosis of the nasal cavity and pharynx. Laryngoscope. 2012;122:2378–2381.
   PubMed Web of Science ®Google Scholar
• Houlton JJ, Donaldson AM, Zimmer L, et al. Intranasal drug-induced fungal rhinopharyngitis. Int Forum Allergy Rhinol. 2012;2:130–134.
   PubMed Web of Science ®Google Scholar
• Vosler PS, Ferguson BJ, Contreras JI, et al. Clinical and pathologic characteristics of intranasal abuse of combined opioid-acetaminophen medications. Int Forum Allergy Rhinol. 2014;4:839–844.
   PubMed Web of Science ®Google Scholar
• Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2010;309:657–659.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Vitalsigns™: opioid painkiller prescribing. 2014 Jul [cited 2015 Oct 20]. Available from: http://www.cdc.gov/vitalsigns/pdf/2014-07-vitalsigns.pdf
   Google Scholar
• Mowry JB, Spyker DA, Cantilena LR Jr, et al. 2013 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol (Phila). 2014;52:1032–1283.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Policy impact: prescription painkiller overdoses. 2011 Nov [cited 2015 Oct 20]. Available from: http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf
   Google Scholar
• Katz NP, Birnbaum H, Brennan MJ, et al. Prescription opioid abuse: challenges and opportunities for payers. Am J Manag Care. 2013;19:295–302.
   PubMed Web of Science ®Google Scholar
• Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24:805–810.
   PubMed Web of Science ®Google Scholar
• Lourenço LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv. 2013;10:229–240.
   PubMed Web of Science ®Google Scholar
• Schaeffer T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol. 2012;8:400–407.
   PubMedGoogle Scholar
• Alexander L, Mannion RO, Weingarten B, et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend. 2014;138:1–6.
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H. Abuse-deterrent formulations: part 1 - development of a formulation-based classification system. Expert Opin Drug Metab Toxicol. 2015;11:193–204.
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies. Expert Opin Drug Metab Toxicol. 2015;16:305–323.
   Web of Science ®Google Scholar
• Food and Drug Administration. Abuse-deterrent opioids: evaluation and labeling guidance for industry. 2015 Apr [cited 2015 Oct 20]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf
   Google Scholar
• Sellers EM, Perrino PJ, Colucci SV, et al. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27:808–816.
   PubMed Web of Science ®Google Scholar
• Harris SC, Perrino PJ, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2014;54:468–477.
   PubMed Web of Science ®Google Scholar
• Colucci SV, Perrino PJ, Shram M, et al. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig. 2014;34:421–429.
   PubMed Web of Science ®Google Scholar
• Katz N, Sun S, Johnson F, et al. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11:303–311.
   PubMed Web of Science ®Google Scholar
• Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29:777–790.
   PubMed Web of Science ®Google Scholar
• Setnik B, Roland CL, Goli V, et al. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients. J Opioid Manag. 2013;9:139–150.
   PubMedGoogle Scholar
• Webster LR, Johnson FK, Stauffer J, et al. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011;11:259–275.
   PubMedGoogle Scholar
• Extended-release hydrocodone (Hysingla ER) for pain. Med Lett Drugs Ther. 2015;57:71–72.
   PubMed Web of Science ®Google Scholar
• Inspiron Delivery Technologies LLC. Inspirion Delivery Technologies receives FDA approval for MorphaBond™ (morphine sulfate) extended-release tablets CII, an opioid analgesic formulated with abuse-deterrent properties. 2015 Oct 5 [cited 2015 Oct 20]. Available from: http://www.prnewswire.com/news-releases/inspirion-delivery-technologies-receives-fda-approval-for-morphabond-morphine-sulfate-extended-release-tablets-cii-an-opioid-analgesic-formulated-with-abuse-deterrent-properties-300153910.html?$G1Ref
   Google Scholar
• Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367:187–189.
   PubMed Web of Science ®Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–358.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–1282.
   PubMed Web of Science ®Google Scholar
• Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–1130.
   PubMed Web of Science ®Google Scholar
• Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, et al. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9–17.
   PubMed Web of Science ®Google Scholar
• Sessler NE, Downing JM, Kale H, et al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23:1238–1246.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry. 2015;72:424–430.
   PubMed Web of Science ®Google Scholar
• Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175:978–987.
   PubMed Web of Science ®Google Scholar
• White AG, LeCates J, Birnbaum HG, et al. Positive subjective measures in abuse liability studies and real-world nonmedical use: potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. J Opioid Manag. 2015;11:199–210.
   PubMedGoogle Scholar
• Kirson NY, Shei A, White AG, et al. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Pain Med. 2014;15:1450–1454.
   PubMed Web of Science ®Google Scholar
• Rossiter LF, Kirson NY, Shei A, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17:279–287.
   PubMedGoogle Scholar
• Cassidy TA, DasMahapatra P, Black RA, et al. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15:440–451.
   PubMed Web of Science ®Google Scholar
• Peacock A, Degenhardt L, Hordern A, et al. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. Int J Drug Policy. 2015 June 7. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• McNaughton EC, Coplan PM, Black RA, et al. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. J Med Internet Res. 2014;16:e119.
   PubMed Web of Science ®Google Scholar